In September 2014, the company received a warning letter from the U.S. Food and Drug Administration requesting that it cease commercial distribution of its infusion pumps and submit a 510(k) application. IRADIMED submitted the 510(k) application on Nov. 24, and it was formally accepted for review by the FDA on Dec. 12. The company stated it will continue to work with the FDA as it conducts its review of the 510(k) submission.
More articles on anesthesia:
17 Lincoln Anesthesiology Group providers join The Physician Network
MEDNAX begins $200M accelerated share repurchase
NAPA to provide exclusive anesthesia services at Southington Surgery Center
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
